Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.

[1]  X. Mariette,et al.  Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. , 2007, Joint, bone, spine : revue du rhumatisme.

[2]  M. Dougados,et al.  Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. , 2005, The Journal of rheumatology.

[3]  Paul Wordsworth,et al.  BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. , 2005, Rheumatology.

[4]  M. Dougados,et al.  Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. , 2005, Joint, bone, spine : revue du rhumatisme.

[5]  Annette Swinkels,et al.  Spinal Position Sense and Disease Progression in Ankylosing Spondylitis: A Longitudinal Study , 2004, Spine.

[6]  J. Braun,et al.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[7]  M. Messow,et al.  Assessment of fatigue in the management of patients with ankylosing spondylitis. , 2003, Rheumatology.

[8]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[9]  M. Dougados,et al.  Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. , 2002, Arthritis and rheumatism.

[10]  A. Garratt,et al.  Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. , 2002, Rheumatology.

[11]  Sinead Brophy,et al.  The natural history of ankylosing spondylitis as defined by radiological progression. , 2002, The Journal of rheumatology.

[12]  G. Jhangri,et al.  A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. , 2002, Arthritis and rheumatism.

[13]  M. Dougados,et al.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? , 1999, Rheumatology.

[14]  N. Bellamy.  Clinimetric concepts in outcome assessment: the OMERACT filter. , 1999, The Journal of rheumatology.

[15]  G. Stucki,et al.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. , 1999, The Journal of rheumatology.

[16]  M. Dougados,et al.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[17]  M. Dougados,et al.  Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. , 1999, The Journal of rheumatology.

[18]  M. Dougados,et al.  Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. , 1999, Rheumatology.

[19]  A. Calin,et al.  The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. , 1998, Arthritis and rheumatism.

[20]  D. Heijde,et al.  8 Measures of outcome in ankylosing spondylitis and other spondyloarthritides , 1998 .

[21]  F. Roudot-thoraval,et al.  Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. , 1997, The Journal of rheumatology.

[22]  M. Dougados,et al.  Predictive factors for the longterm outcome of spondyloarthropathies. , 1994, The Journal of rheumatology.

[23]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[24]  M. Dougados,et al.  [Comparison of patients evaluated for spondylarthropathy in France and Morocco]. , 1993, Revue du rhumatisme.

[25]  J P Nakache,et al.  Evaluation of a functional index for patients with ankylosing spondylitis. , 1990, The Journal of rheumatology.

[26]  J. Simpson,et al.  Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. , 1987, Annals of the rheumatic diseases.

[27]  M. R. Laurent,et al.  Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. , 1983, Annals of the rheumatic diseases.

[28]  J. Fermanian,et al.  Psychometric properties of the bath ankylosing spondylitis disease activity index (BASDAI): comparison of the different versions available in English. , 2006, Clinical and experimental rheumatology.

[29]  M. Kokko,et al.  Age and spinal mobility in ankylosing spondylitis. , 1995, Scandinavian journal of rheumatology.